WCN26-4321 EFFECTS ON SERUM POTASSIUM AND RISK OF HYPERKALAEMIA WITH BALCINRENONE AND DAPAGLIFLOZIN; A SUB ANALYSIS OF THE PHASE 2b MIRO-CKD TRIAL IN PATIENTS WITH CKD

Read full text Summarise with VIRAT
Authors: Hiddo J.L. Heerspink, Erika De Sousa Amorim, Anna Eriksson, Nicolas Jose Guzman, Maria Leonsson‐Zachrisson, Yunyun Jiang, Patrick Barry Mark
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Despite clinical benefits of sodium glucose co-transporter-2 inhibitors (SGLT2i), recommended by current guidelines for the treatment of chronic kidney disease (CKD), there is still an unmet need for managing residual risk of disease progression. Balcinrenone is a novel, non-steroidal mineralocorticoid receptor antagonist (MRA) expected to maintain the cardio-renal benefits of MR antagonists with a reduced risk of hyperkalaemia based on pre-clinical data. Balcinrenone in combination with dapagliflozin may provide complementary and additive kidney and cardiovascular protection.

Fields of Study & Subjects

Potassium and Related Disorders Chronic Kidney Disease and Diabetes Hormonal Regulation and Hypertension

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104776–104776
Publication date
25 March 2026
Language
EN